Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$0.98 -2.0%	$0.98	$0.61 ▼ $6.00	$15.08M	0.08	491,438 shs	262,920 shs
CYCC Cyclacel Pharmaceuticals	$8.89 -0.1%	$7.49	$3.08 ▼ $597.60	$14.10M	0.08	1.86 million shs	90,286 shs
MRKR Marker Therapeutics	$1.25 -3.1%	$1.51	$0.95 ▼ $5.95	$14.60M	1.45	3.48 million shs	139,542 shs
REVB Revelation Biosciences	$2.58 +2.4%	$2.57	$2.11 ▼ $168.00	$4.28M	-0.06	185,265 shs	119,284 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	-2.01%	-0.67%	-2.99%	-5.79%	-79.26%
CYCC Cyclacel Pharmaceuticals	-0.11%	-0.89%	-27.90%	-70.37%	-97.45%
MRKR Marker Therapeutics	-3.10%	+1.63%	-20.38%	+12.61%	-62.24%
REVB Revelation Biosciences	+2.38%	+1.18%	-10.10%	-71.80%	-94.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	3.3826 of 5 stars	3.5	5.0	0.0	3.3	0.0	1.3
CYCC Cyclacel Pharmaceuticals	1.7494 of 5 stars	0.0	4.0	0.0	4.4	2.5	0.0
MRKR Marker Therapeutics	4.4582 of 5 stars	3.8	5.0	3.9	3.3	0.0	0.6
REVB Revelation Biosciences	0.1708 of 5 stars	0.0	2.0	0.0	1.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	3.00	Buy	$9.00	818.55% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	953.33% Upside
REVB Revelation Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest REVB, ALLR, CYCC, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/28/2025	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
CYCC Cyclacel Pharmaceuticals	$40K	351.16	N/A	N/A	($58.87) per share	-0.15
MRKR Marker Therapeutics	$6.59M	2.15	N/A	N/A	$1.73 per share	0.72
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-147.94%	-90.33%	8/18/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-3,648.09%	-145.49%	N/A
MRKR Marker Therapeutics	-$10.73M	-$1.33	N/A	N/A	N/A	-224.46%	-101.87%	-83.02%	N/A
REVB Revelation Biosciences	-$15.04M	-$68.61	N/A	N/A	N/A	N/A	-240.27%	-148.95%	N/A

Latest REVB, ALLR, CYCC, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	N/A	ALLR Allarity Therapeutics	-$0.21	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	MRKR Marker Therapeutics	-$0.55	-$0.29	+$0.26	-$0.29	$0.72 million	N/A
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A
8/7/2025	Q2 2025	REVB Revelation Biosciences	-$4.46	-$7.01	-$2.55	-$7.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.66	2.66
CYCC Cyclacel Pharmaceuticals	N/A	5.60	5.60
MRKR Marker Therapeutics	N/A	6.79	6.79
REVB Revelation Biosciences	N/A	3.42	3.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
CYCC Cyclacel Pharmaceuticals	23.58%
MRKR Marker Therapeutics	22.39%
REVB Revelation Biosciences	12.80%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.08%
CYCC Cyclacel Pharmaceuticals	51.20%
MRKR Marker Therapeutics	7.80%
REVB Revelation Biosciences	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.08 million	15.07 million	Not Optionable
CYCC Cyclacel Pharmaceuticals	14	1.58 million	773,000	Optionable
MRKR Marker Therapeutics	60	11.31 million	10.43 million	Not Optionable
REVB Revelation Biosciences	10	1.70 million	1.66 million	Not Optionable

REVB, ALLR, CYCC, and MRKR Headlines

Recent News About These Companies

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

August 8, 2025 | businesswire.com

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

July 16, 2025 | businesswire.com

Revelation Biosciences to implement 1-for-3 reverse stock split

July 2, 2025 | investing.com

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - Morningstar

July 2, 2025 | morningstar.comM

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

July 1, 2025 | businesswire.com

Revelation Biosciences Inc News (REVB) - Investing.com

June 24, 2025 | investing.com

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

May 31, 2025 | finance.yahoo.com

Revelation Biosciences sets terms for $4 million public offering

May 30, 2025 | investing.com

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

May 29, 2025 | insidermonkey.com

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

May 29, 2025 | businesswire.com

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 29, 2025 | finance.yahoo.com

Revelation Biosciences board member steps down amid new focus

May 25, 2025 | uk.investing.com

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 23, 2025 | businesswire.com

REVB On Track and Exploring New Markets

May 9, 2025 | msn.com

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, ...

May 8, 2025 | gurufocus.com

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

April 29, 2025 | businesswire.com

Why Revelation Biosciences Inc. (REVB) Went Down On Thursday?

April 10, 2025 | msn.com

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

March 17, 2025 | businesswire.com

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

March 13, 2025 | businesswire.com

Revelation Biosciences reports Q4 EPS ($4.98) vs ($133.64) last year

March 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, ALLR, CYCC, and MRKR Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$0.98 -0.02 (-2.01%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.98 0.00 (-0.49%)

As of 04:10 AM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.89 -0.01 (-0.11%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$9.02 +0.14 (+1.52%)

As of 04:25 AM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Marker Therapeutics NASDAQ:MRKR

$1.25 -0.04 (-3.10%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.01 (+1.20%)

As of 08/14/2025 07:03 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Revelation Biosciences NASDAQ:REVB

$2.58 +0.06 (+2.38%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.50 -0.08 (-3.26%)

As of 08/14/2025 05:23 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time